Connect with us

Markets and industry

UK Home Office grants high-THC medical cannabis licence for £300,000 research facility

Construction on the purpose-built facility in Lincolnshire is expected to commence in July.

Published

on

DJT Plants will grow medical cannabis in the UK for research trials

A UK firm has been granted a Home Office licence to grow high-THC medical cannabis for research purposes. 

Cannabis investment firm Ananda Developments has secured a licence from the UK Home Office to grow cannabis with THC levels of greater than 0.2 percent. 

Its subsidiary, DJT Plants – the farmers behind GW Pharmaceuticals’ Epidiolex trials – will grow 65 strains for use in large-scale research, focusing on the conditions for which cannabis products are being prescribed in the UK.

Subject to further Home Office licensing, DJT Plants intends to move to commercial growing, with the aim of supplying high-quality and consistent products to UK patients, as well as exporting to Europe.

Construction on the £300,000 purpose-built facility in Lincolnshire is expected to commence in July.

The site will include a laboratory, indoor breeding spaces and clean and secure areas for handling the harvested flower.

Two greenhouses will also be constructed adjacent to the facilities to accommodate the field trials. The whole research facility will be fenced, secured and monitored. 

Stabilising up to 65 strains

Thirteen strains have been chosen for the trials, with five seeds of each strain to be planted to create a total of 65 potential strains.

The chosen strains exhibit a range of profiles, based on current prescribing and researched information, including: low-THC/high-CBD, high-THC/low-CBD and balanced THC/CBD content.

From the 65 genetically stable strains, a selection will be made to match the best resulting strains with medical conditions.

Ananda Developments CEO, Melissa Sturgess.

Speaking to Cannabis Health, Ananda Developments CEO, Melissa Sturgess said: “All the material that we currently have in the UK is imported, and quality and consistency seems to be variable. 

“I think there’s a huge opportunity to provide a UK source of medicinal cannabis for both UK and international patients.

“Our aim is to have our own unique strains that will be suitable for the indications that are being treated in the UK, and will be plants or chemovars that thrive in UK conditions.

She continued: “Stabilising these 65 strains is about getting the genetics to the point where plant after plant after plant, you’re getting exactly the same cannabinoid profile. 

“We’re also very focused on terpenes which is fairly cutting-edge in terms of where medicinal cannabis is at the moment.

“While the research is thinking about terpenes, there isn’t much focus on the terpenes when it comes to the flower that is being offered.”

Growing sustainably 

DJT Plants will use the UK’s natural growing season, during which the facility will benefit from long hours of light and its greenhouses will create the right temperature to avoid having to rely on artificial light and heat. 

Its material will then be sent to Israel for cannabinoid and terpene analysis. 

“When you grow under artificial conditions of light and heat, the power that is consumed is astronomical, so whilst we talk about this natural product, we’re ignoring the fact that actually it can be really damaging,” said Sturgess.

“Patients and prescribing doctors will know they’re getting a UK product, which hasn’t travelled very far, meaning it’s probably going to be fresher, hasn’t chewed up power or transportation costs coming from the other side of the world and it will be consistent and of a high-quality.”

Markets and industry

Curaleaf partnership to build platform for German recreational market

The company has entered into a strategic partnership with Germany’s Four 20 Pharma.

Published

on

Curaleaf partnership to build platform for Germany's recreational market
Image credit: artbutenkov
Home » News » UK Home Office grants high-THC medical cannabis licence for £300,000 research facility

Curaleaf has acquired a 55 per cent stake in Four 20 Pharma – a fully EU-GMP and GDP licensed German producer and distributor of medical cannabis with its own product line.

Germany currently represents the largest medical cannabis market in Europe, with a total addressable market of over €200m (~£m) in 2022. This is expected to grow to nearly €1bn by the end of 2024 with the expected legalisation of recreational cannabis, expected to begin in late 2023 or early 2024.

Four 20 Pharma is one of the largest cannabis operators in Germany, with a greater than 10 per cent market share.

Read more: Curaleaf is championing social impact in the cannabis industry

The partnership creates a strategic pathway for Curaleaf to acquire complete control of Four 20 Pharma within two years of the commencement of adult use in Germany. Curleaf has stated that the partnership also ensures alignment between Curaleaf and Four 20 Pharma’s current management team to rapidly build a best-in-class German business and a strong platform for Germany’s eventual adult use market. 

Curaleaf executive chairman, Boris Jordan, commented: “By partnering with Four20 Pharma, Curaleaf’s European business will immediately gain additional critical mass and be in a superior position to capitalise on the accelerating trends in the European cannabis market.

Read more: Curaleaf completes landmark registration of cannabis products in Malta

“The opportunity in Europe cannot be understated, and Curaleaf is uniquely differentiated from other US MSOs via our already significant presence as the largest and most licensed cannabis company in Europe. 

“With cultivation facilities in Portugal, manufacturing facilities in Spain and UK, rapidly growing patient numbers across Europe, particularly in the UK, Curaleaf serves the entire legal cannabis ecosystem and is also poised to capitalise on the adult use opportunity as regulation starts to unlock.

“This strategic transaction further underscores our aspiration to be the major player in the European market and the leading global cannabis company.”

President of Curaleaf International, Miles Worne, said: “Four 20 Pharma is a leading German distributor with a branded product that consumers love. They’ve captured significant market share in Germany by sourcing product from top EU-GMP certified suppliers around the world and building strong connections with German medical consumers by providing the highest quality flower in a namesake branded offering. 

“As such, Four 20 Pharma is uniquely positioned to capitalise on Germany’s conversion from a medical to an adult use market and we’re thrilled to be partnering with their talented management team.”

Managing Partner of Four 20 Pharma, Torsten Greif, commented: “We have been exploring possible partners to stake our claim in the future German and European cannabis markets, and in Curaleaf we know we’ve found the undisputed leader and the best partner. 

“From the beginning of our conversations, it was clear that they supported our strategic vision and respected our autonomy and entrepreneurial approach. Having full access to the tremendous knowledge and assets of the Curaleaf team will accelerate our future growth projects and help drive our company to the next level.”

Managing partner of Four 20 Pharma, Thomas Schatton, added: “Curaleaf shares our values of customer dedication and commitment to product quality, and we are incredibly excited about our future together. 

“The team at Four 20 are thrilled to be able to leverage Curaleaf’s proven R&D expertise to help us continue delivering the best quality products to our medical patients and the promising future  market.”

Continue Reading

Markets and industry

MGC Pharma receives first tranche of funding under new $10m financing facility

The financing facility will fund the execution of MGC Pharma’s business commercialisation strategy in the UK and US.

Published

on

MGC Pharma receives forst trache of funding from Mercer Street

MGC Pharmaceuticals has confirmed it has received the first funding tranche of US$1.2m under a new US$10 million financing facility with Mercer Street Global Opportunity Fund.

The injection of funding will be used to further MGC Pharma’s business strategy, focused primarily on developing revenue growth through its partnerships with Sciensus Rare in the UK and Europe and AMC in the US.

The Mercer Street Global Opportunity Fund is managed by Mercer Street Capital Partners, a United States-based institutional fund manager and MGC Pharma’s largest shareholder.

The first portion of funding has been received in full and MGC Pharma will now issue 1.32m of convertible notes with a face value of US$1.00 each to Mercer Street. The company will also issue 21,511,545 fully paid ordinary shares to Mercer as part of the agreement.

The US$10m financing facility provides MGC Pharma with access to significant capital to fund the execution of its business commercialisation strategy in the UK and US as well as advance regulatory approvals for the company’s proprietary products in an effort to drive revenue growth, assist in the rollout of the ZAM App and provide funding for the group’s general corporate expenses.

The company will continue to implement “significant” non-revenue driving cost reductions within its operations, including the delay of non-core clinical trials.

Roby Zomer, co-founder and managing director of MGC Pharma, commented: “Mercer’s new US$10m finance facility provides the company with access to funding for MGC Pharma to continue to execute its business strategy of opening up key strategic markets over the next six months. During this period the business strategy will focus primarily on generating revenue growth through our existing relationships with Sciensus Rare in the UK and Europe, and AMC in the USA.

“In addition to its sales growth strategy, MGC is very excited about the potential value that the recent 40 per cent acquisition of the ZAM medical data collection App and its associated machine learning algorithm bring to the company.

“This investment is not only aimed at reducing R&D costs and providing the company with critical proprietary clinical data in the future but also provides the MGC with the potential for a future additional revenue stream and a value-creating asset on the back of the software’s successful implementation and rollout.”

The new US$10m financing facility fully funds MGC Pharma’s current business plan, the company said, and replaces the unused A$9.25 million of the previous funding facility established in September 2021.

Home » News » UK Home Office grants high-THC medical cannabis licence for £300,000 research facility

Continue Reading

Markets and industry

Love Hemp sees sales drop by 16%, expects revenues of £3.6m

Published

on

Love Hemp sees sales drop by 16%, expects revenues of £3.6m
Home » News » UK Home Office grants high-THC medical cannabis licence for £300,000 research facility

Love Hemp Group has stated it is expecting to report total revenues of £3.6m for the financial year ending 30 June 2022, which it says represents revenues slightly ahead of management expectations.

The lower than expected financing earlier this year has resulted in significant reductions in marketing programmes, says Love Hemp. However, the company still experienced sales growth during the second half of the year.

The company’s revenue continues to be UK-centric with year-on-year growth delivered in major retail stores, showing revenue of £2.15m in FY22 up 19 per cent, compared to £1.78m in FY21.

Read more: Love Hemp CBD brand to launch on eBay

Direct to Consumer (DTC) sales continue to be slow via the company’s own online channels, lovehemp.com and cbdoilsuk.com but have generated 7437 new customers. The company has stated that these sales represent 26 per cent of total revenue, down from a 59 per cent share of total revenue compared in FY21, with a new head of digital commerce having been appointed to help grow DTC sales.

However, it has also highlighted that it has sold 233,987 units, up 19 per cent from last year. 

Read more: Love Hemp to appoint new AQSE corporate advisor

This year, Love Hemp had all 34 products added to the Novel Foods Register. As a result, it has agreed new major retail listings and anticipates launching a range of its products in these new stores and respective online platforms in Q4 of 2022. 

Additionally, the company has advanced discussions with a number of other major retailers interested in stocking Love Hemp products.

Tony Calamita, CEO commented; “I am delighted that we have continued to expand our footprint with greater distribution into major retail stores and delivered record sales of product units so more consumers than ever are benefiting from our products. 

“This has been achieved whilst undertaking a significant operational review and I am confident this growth will continue.

“The company plans to make Love Hemp more visible internationally and sales overseas provides a significant opportunity in the future. We are a dynamic and passionate brand that after some challenges is once again on a growth curve with the most powerful and influential brand partnerships in the sector. Now it is our time to really capitalise on the opportunity.”

In December 2021 Love Hemp was also awarded ‘Leading CBD brand 2021’ in the Commercial Cannabis awards organised by Global Health and Pharma. Love Hemp is also a nominated finalist for ‘Most Loved CBD brand’ in the World CBD awards due to take place in October 2022.

Over the next year, Love Hemp plans to invest further in product development and release numerous new products in both ingestible and topical formats.

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts

[class^="wpforms-"]
[class^="wpforms-"]